About US
Contact us
-
China obtains ISO/TC150/SC7 voting rightsOn March 26, 2013, the secretariat of Tissue Engineered Medical Products Subcommittee of National Technical Committee on Implants for Surgery and Orthopedic Devices of Standardization Administration2013/4/8
-
India's top court rebuffs Merck, lets generic Januvia roll outIndia's Supreme Court is keeping the pressure on Western drugmakers. Just days after invalidating a patent for Novartis' ($NVS) cancer drugGlivec, it has said a generic drugmaker there is free, for2013/4/7
-
Roche's Tamiflu, GSK's Relenza work against new bird flu strainChina will lean on the Roche ($RHHBY) drugTamifluto treat those infected with a new strain of bird flu that has so far sickened 16, killing 6. Authorities in Shanghai emphasized that the H7N9 virus i2013/4/7
-
Merz swoops into Obagi deal with $385M bid, topping ValeantThese days, dermatology is the belle of the ball. Drugmakers have been wooing small players in the skin-treatment field, and just last month, Valeant Pharmaceuticals ($VRX) announced that it had agre2013/4/3
-
Lilly bets on new insulin products with $180M plant additionEli Lilly ($LLY) has made a huge bet on insulin to help it maneuver past patent losses for drugs like antidepressant Cymbalta which falls off this year. It has four new products in development, inclu2013/4/3
-
J&J faces big spending, big rivals for new diabetes drug InvokanaJohnson & Johnson's new diabetes drug Invokana, previously known as canagliflozin, is the first FDA-approved treatment in a new class. That's something of a double-edged sword. It offers the prom2013/4/2
-
As Novartis loses Glivec bid, India's war on pharma patents threatens to spreadNovartis ($NVS) lost its last bid for an Indian patent on its cancer drug Glivec. As the nation's Supreme Court prepared to rule Big Pharma braced itself for impact. India has blazed a patent-slashin2013/4/2
-
Alexion gets FDA warning but doesn't expect Soliris disruptionAlexion is facing a tough situation for a one-hit wonder. It has been issued an FDA warning letter for its manufacturing plant where it makes its only approved drug--the rare-disease, and very pricey2013/4/1
-
Drugmakers need to think local in emerging markets, execs sayDrugmakers know by now that emerging markets aren't a quick fix. Though fast-developing countries such as China and India offer the promise of fast growth in drug sales, it's more difficult to tap th2013/4/1
-
Roche's Japanese arm gets green light for new arthritis drug trialChugai has been given the go-ahead to start clinical trials of its new arthritis treatment in Japan. The Japanese subsidiary of Roche has confirmed that regulators in the country have given the offic2013/3/29